Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...

On Today with Claire Byrne, Maura Fay reports on the rollout of Mounjaro in Ireland and speaks to medical experts about issues surrounding access to this medication. Listen back above. The most ...

With social media's history of hyped-up health trends, does a 'Mounjaro drink' drink deliver results - or is it just another internet myth? From 'sleepy girl cocktails' to 'oatzempic' drinks there ...

Eli Lilly (NYSE:LLY) reported strong Q4 2024 results on Thursday, surpassing Wall Street estimates, driven by a more than twofold increase in sales of its weight loss and diabetes drugs Mounjaro ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound ...

Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a big revenue increase Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound ...

I was upfront. I don’t have any reason to go sell some other stuff. I told you, I took my Mounjaro. I used Mounjaro, okay? That is what I did.” The EGOT winner was indeed upfront ...

Goldberg said the company "melded" a CBS News Sunday Mornings appearance from her to sell “bad weight loss drugs." ...

The General Pharmaceutical Council clampdown means people will no longer be able to get prescriptions for injections of drugs like Wegovy or Mounjaro after just completing a patient questionnaire.

Eli Lilly's weight-loss jab Mounjaro has been cleared for rollout by the NHS in England, with around 3.4 million people eligible, but will be made available in stages to limit the financial impact.

The launch of Mounjaro always raised the risk that it would cannibalise sales of Lilly's own GLP-1 agonist Trulicity (dulaglutide), which is competing head-to-head with Ozempic in the market, but ...